A series of double-component, bis O.sup.2-aryl diazeniumdiolate derivatives are provided, of which each molecule can release up to four nitric oxide molecules. These compounds show cytotoxic activities to cancer cells, such as human leukemia, breast cancer and lung cancer. Among them, the compound 3 showed the highest specific activity against human leukemia cells.

The present invention relates to: a polymerizable compound represented by a formula (I); a polymerizable composition comprising the polymerizable compound and an initiator; a polymer obtained by polymerizing the polymerizable compound or the polymerizable composition; and an optically anisotropic article comprising the polymer [in the formula, Y.sup.1 to Y.sup.8 are a chemical single bond, O, OC(O), C(O)O, or the like; G.sup.1 and G.sup.2 are a divalent aliphatic group having 1 to 20 carbon atoms, or the like; Z.sup.1 and Z.sup.2 are an alkenyl group having 2 to 10 carbon atoms, or the like; A.sup.1 is a tetravalent aromatic group, or the like; A.sup.2 and A.sup.3 are a divalent alicyclic hydrocarbon group having 3 to 30 carbon atoms, or the like; A.sup.4 and A.sup.5 are a divalent aromatic group having 4 to 30 carbon atoms, or the like; A.sup.x1 and A.sup.x2 are an organic group having 2 to 30 carbon atoms that includes an aromatic ring, or the like; A.sup.y1 and A.sup.y2 are a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; Q.sup.1 and Q.sup.2 are a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; and m and n are 0 or 1]. According to the present invention, a polymerizable compound, a polymerizable composition, and a polymer that have a practical low melting point, exhibit excellent solubility in a general-purpose solvent, can be produced at low cost, and can produce an optical film that achieves uniform conversion of polarized light over a wide wavelength band, and also provide an optically anisotropic article. ##STR00001##

The present invention relates to: a polymerizable compound represented by a formula (I); a polymerizable composition comprising the polymerizable compound and an initiator; a polymer obtained by polymerizing the polymerizable compound or the polymerizable composition; and an optically anisotropic article comprising the polymer [in the formula, Y.sup.1 to Y.sup.8 are a chemical single bond, O, OC(O), C(O)O, or the like; G.sup.1 and G.sup.2 are a divalent aliphatic group having 1 to 20 carbon atoms, or the like; Z.sup.1 and Z.sup.2 are an alkenyl group having 2 to 10 carbon atoms, or the like; A.sup.1 is a tetravalent aromatic group, or the like; A.sup.2 and A.sup.3 are a divalent alicyclic hydrocarbon group having 3 to 30 carbon atoms, or the like; A.sup.4 and A.sup.5 are a divalent aromatic group having 4 to 30 carbon atoms, or the like; A.sup.x1 and A.sup.x2 are an organic group having 2 to 30 carbon atoms that includes an aromatic ring, or the like; A.sup.y1 and A.sup.y2 are a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; Q.sup.1 and Q.sup.2 are a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; and m and n are 0 or 1]. According to the present invention, a polymerizable compound, a polymerizable composition, and a polymer that have a practical low melting point, exhibit excellent solubility in a general-purpose solvent, can be produced at low cost, and can produce an optical film that achieves uniform conversion of polarized light over a wide wavelength band, and also provide an optically anisotropic article. ##STR00001##

The present invention provides, inter alia, a compound having the structure:

##STR00001##

Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.

The present invention provides, inter alia, a compound having the structure:

##STR00001##

Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.

A series of double-component, bis O.sup.2-aryl diazeniumdiolate derivatives are provided, of which each molecule can release up to four nitric oxide molecules. These compounds show cytotoxic activities to cancer cells, such as human leukemia, breast cancer and lung cancer. Among them, the compound 3 showed the highest specific activity against human leukemia cells.

A series of double-component, bis O.sup.2-aryl diazeniumdiolate derivatives are provided, of which each molecule can release up to four nitric oxide molecules. These compounds show cytotoxic activities to cancer cells, such as human leukemia, breast cancer and lung cancer. Among them, the compound 3 showed the highest specific activity against human leukemia cells.

Triazenes and methods of producing diazonium species from said traizenes using ultraviolet (UV) light, which provide a fast, easy, stable, scalable, and selectively-triggerable means of modifying aromatic nucleophiles, including those on protein surfaces. Thus, the present invention also includes triazenes for use as bioconjugates, e.g., for use in protein modification, for use as probes (including but not limited to detectable probes such as fluorescent probes), protein crosslinking, etc.

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.